Tesamorelin reduces deep abdominal fat by roughly 15–18% in 26 weeks, measured by MRI, in placebo-controlled trials, without dieting. That single fact does more to explain its place in the fat-loss conversation than any general claim about “boosting metabolism” or “burning fat.”
It’s also why tesamorelin is one of the few peptides in this category that is actually FDA-approved, manufactured, and prescribable as a brand-name drug (Egrifta SV and the newer Egrifta WR), not compounded, not gray-market.
What that means practically: this is a peptide with a real clinical evidence base, a specific mechanism, a defined dosing protocol, and a narrow set of people it’s genuinely right for. It’s not a weight-loss drug. It’s a visceral-fat drug, and once you understand the difference, the decision about whether tesamorelin makes sense for you becomes much sharper.
What tesamorelin actually does, and the part most articles skip
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH), the natural signal your hypothalamus uses to tell your pituitary gland to release growth hormone (GH). The molecule has been modified at one end to resist breakdown in the bloodstream, which is what gives it enough duration to produce a meaningful clinical effect.
When you inject it, three things happen in sequence:
- Your pituitary (the small gland at the base of your brain that releases GH) responds to the GHRH signal and releases a pulse of growth hormone
- That GH pulse travels to the liver, which produces IGF-1 (insulin-like growth factor 1, the downstream hormone GH stimulates), and IGF-1 is the marker most clinics actually track on bloodwork
- The elevated GH activates hormone-sensitive lipase, an enzyme inside fat cells that breaks stored fat down into free fatty acids the body can burn
Tesamorelin doesn’t burn fat “everywhere.” It preferentially reduces visceral adipose tissue (VAT), the deep abdominal fat that wraps around your organs, far more than it reduces subcutaneous fat (the pinchable fat under your skin). That distinction is the entire reason tesamorelin exists as a drug. It is not, mechanistically, a tool for reducing pinchable belly fat or general overweight. It is a tool for reducing the metabolically dangerous fat that drives insulin resistance, fatty liver, and cardiovascular risk.
Key takeaway: Tesamorelin restores your body’s own GH pulses, which preferentially breaks down deep visceral fat. The scale may move modestly. The waistline almost always moves more, because the fat being lost is the kind that distends the abdomen from the inside.
What the clinical trials actually showed
Tesamorelin earned its FDA approval through two large randomized placebo-controlled trials known as LIPO-1 and LIPO-2, run in patients with HIV-associated lipodystrophy (a condition that causes severe visceral fat accumulation). The trials are worth knowing because they’re the actual data behind every clinic’s claims, and the numbers are far more specific than most marketing pages suggest.
| Outcome | What the trials showed |
| Visceral fat reduction | ~15–18% reduction in visceral adipose tissue at 26 weeks, MRI-measured |
| Waist circumference | Average reduction of ~2 cm at 26 weeks |
| Subcutaneous fat | Not significantly reduced, confirming the visceral-specific effect |
| Lean body mass | Preserved or slightly increased |
| IGF-1 | Increased substantially (often 80%+ from baseline) |
| Triglycerides | Reduced |
| Time to first measurable effect | ~3 months; full effect by month 6 |
Two patterns underneath that table matter for setting expectations:
- The fat loss is real but not dramatic. A 15–18% reduction in visceral fat is clinically meaningful, it correlates with measurable improvements in metabolic and cardiovascular risk markers. But it is not the kind of weight loss someone using semaglutide or tirzepatide experiences. The visible change is usually a flatter midsection, not a substantially smaller body.
- The timeline is slow. Most patients don’t see meaningful change before month 2–3. Full effect lands at month 6. Anyone evaluating tesamorelin at week 4 is judging it before it’s had time to work.
Trials also documented: when tesamorelin is stopped, visceral fat tends to return over the following months. This isn’t a quirk, it’s how hormonal fat-loss therapies generally behave. The drug is doing the work; stopping the drug stops the work. We’ll come back to this in the “what to expect” section, because it shapes whether tesamorelin makes sense for your goals.
Tesamorelin vs. GLP-1s (semaglutide, tirzepatide): different tools, different jobs
This is the comparison most people are actually trying to make right now, and it’s worth getting right. Tesamorelin and GLP-1 medications are not competitors. They do different things, through different mechanisms, with different outcomes, and in some cases they’re combined.
| Factor | Tesamorelin | GLP-1s (semaglutide, tirzepatide) |
| Mechanism | Stimulates own GH → activates fat breakdown enzymes | Suppresses appetite, slows gastric emptying, regulates blood sugar |
| Primary target | Visceral (deep abdominal) fat specifically | Total body weight (fat + some lean mass) |
| Magnitude of weight loss | Modest scale change; major waist change | Substantial total weight loss (10–22% body weight) |
| Effect on muscle | Preserves / slightly increases lean mass | Some lean mass loss is typical |
| Dosing | Daily subcutaneous injection (bedtime, fasted) | Weekly subcutaneous injection |
| Cost | High (multiple thousands/month at retail, off-label rarely covered) | High but increasingly insurance-covered for obesity/diabetes |
| Best for | Visceral fat, metabolic risk, body recomposition | Total weight loss, obesity, type 2 diabetes |
The cleanest way to think about it: GLP-1s shrink the whole body; tesamorelin shrinks the visceral compartment specifically. A person with moderate overall weight but a large, hard belly distended by visceral fat may benefit more from tesamorelin. A person with significant overall obesity will get more from a GLP-1. Some patients, especially those who reach a body-composition plateau on a GLP-1 with stubborn central adiposity remaining, are now using both, sequentially or concurrently, under physician supervision.
The trade-off: tesamorelin gives you a precision tool for one specific problem. GLP-1s give you a broader-spectrum weight-loss tool. Neither replaces the other; choosing between them is a question of which problem you actually have.
Dosing, timing, and what to expect at weeks 4, 12, and 26
Tesamorelin is dosed at 2 mg subcutaneously, once daily, in the FDA-approved protocol. This is the standard regardless of brand (Egrifta SV or Egrifta WR, the newer reformulation requires less reconstitution but the active dose is equivalent).
Tesamorelin works by stimulating a GH pulse, and your pituitary’s responsiveness to GHRH is suppressed by insulin. After meals, insulin is high, and the same dose of tesamorelin produces a smaller GH pulse.
Dosing at bedtime, in a fasted state does two things at once: it sidesteps post-meal insulin interference, and it stacks the pharmacological GH pulse on top of your body’s natural overnight GH surge. Same drug, wrong time, much of the benefit wasted.
Realistic timeline
| Time on therapy | What typically changes |
| Weeks 1–4 | IGF-1 rises (measurable on bloodwork). Some patients notice improved sleep quality. Mild fluid retention possible. Visible changes uncommon. |
| Weeks 4–12 | Subjective improvements in energy, recovery, sleep. Waist circumference may begin to decrease modestly. Body weight on the scale often barely moves, this is expected. |
| Weeks 12–26 | The window where most of the visible visceral fat reduction happens. Waist circumference reduction, flatter abdomen, measurable VAT reduction on imaging if checked. |
| Beyond 26 weeks | Effect plateaus; continued use maintains the result. Stopping leads to gradual regain of visceral fat over the following months. |
The expectation that causes the most disappointment: scale weight. Tesamorelin is not designed to drop scale weight dramatically. It’s designed to redistribute body composition by removing the most metabolically harmful fat compartment. A person who finishes 6 months on tesamorelin may be only a few pounds lighter, but with a meaningfully smaller waist, better metabolic labs, and preserved muscle. That is the win, and it’s worth knowing it ahead of time.
Side effects, monitoring, and the rebound to know about
Tesamorelin’s safety profile is well-characterized, it has been on the US market since 2010, with extensive post-market data in addition to the original trials.
Common, usually mild:
- Injection-site reactions (redness, bruising, mild swelling), most frequent
- Mild fluid retention in the first 1–2 weeks as IGF-1 rises
- Joint stiffness or mild arthralgia
- Headache or flushing after injection
Less common, dose- or response-related:
- Carpal-tunnel-like wrist symptoms (sign IGF-1 may be too high)
- Elevated fasting glucose / mild insulin resistance, GH antagonizes insulin
- Peripheral edema persisting beyond the first few weeks
- Skin sensitivity at injection sites
The monitoring that matters. IGF-1 should be checked at baseline, then every 3 months on therapy. It’s the marker that tells you whether you’re in a therapeutic range or pushing past it. Fasting glucose and HbA1c should also be tracked, especially in patients with any insulin resistance at baseline, because GH-mediated fat breakdown can transiently worsen glycemic control before the metabolic benefits of reduced visceral fat catch up.
The rebound. This is the part that shapes whether tesamorelin makes sense for your goals. Visceral fat tends to return over the months after stopping the drug, typically reaching pre-treatment levels within 6–12 months off therapy. This is not a failure of the drug. It’s how hormonal fat therapies work generally: when the signal stops, the underlying drivers of visceral fat accumulation reassert themselves.
Practically, this means tesamorelin is most useful when paired with a sustainable approach to the underlying lifestyle drivers (diet quality, training, sleep, stress) so that the body composition gains don’t fully reverse when therapy ends.
The trade-off: tesamorelin is highly effective at what it does and well-tolerated for most patients, but the result is maintained only as long as therapy continues, or as long as lifestyle changes have done enough work to hold the result without it.
Who tesamorelin is, and isn’t, for
Tesamorelin is a precision tool, not a general weight-loss drug. The patients who get the most from it have a specific profile.
A good fit for tesamorelin:
- Excess visceral fat specifically, measured waist circumference elevated (>40 in / 102 cm for men, >35 in / 88 cm for women) despite acceptable overall weight
- Metabolic risk markers (elevated triglycerides, fatty liver, mild insulin resistance) driven by central adiposity
- Plateau in body composition despite consistent training and nutrition
- Patients who’ve reached a desired total weight on a GLP-1 but retain a disproportionate central fat distribution
- Adults with age-related GH decline contributing to changes in body composition
Not a good fit:
- Normal-weight individuals seeking cosmetic fat loss, tesamorelin is not a physique drug for already-lean people, and the side-effect profile isn’t worth it for that goal
- Active or recent cancer, GH and IGF-1 can stimulate growth of some malignancies; this is the most important contraindication
- Severe uncontrolled diabetes, GH antagonizes insulin and can worsen glycemic control
- Active proliferative diabetic retinopathy
- Pregnancy or breastfeeding
- Pituitary disorders or recent pituitary surgery
Anyone considering tesamorelin should have a baseline workup that includes IGF-1, fasting glucose, HbA1c, a lipid panel, and a careful medical history, not just to establish baselines for monitoring, but to confirm tesamorelin is mechanistically the right tool before starting.
Cost and what FDA approval changes about your decision
This is the part that affects access more than most patients expect, and it’s worth being clear-eyed about before considering therapy.
The good news first. Tesamorelin is one of the few peptides in this category that is FDA-approved as a finished pharmaceutical product. Egrifta SV and Egrifta WR are manufactured under standard pharmaceutical quality controls, not compounded in a back room. That distinction matters substantially in the current peptide landscape, where the FDA has restricted many compounded peptides and supply chains have become unreliable. With tesamorelin, what you’re prescribed is what you’re getting.
The cost reality. Brand-name tesamorelin is genuinely expensive. Retail pricing typically runs in the multiple-thousands-of-dollars-per-month range. Insurance coverage is generally limited to the on-label indication (HIV-associated lipodystrophy); off-label use for visceral fat reduction in HIV-negative patients is rarely covered.
This creates a real choice point. Some patients absorb the cost because the FDA-approved supply, the documented evidence base, and the manufacturing oversight are worth it to them. Others look at compounded GHRH analogs (CJC-1295, sermorelin) as cheaper alternatives, accepting that those are different molecules with different evidence bases and, in some cases, uncertain supply chains.
There is no compounded peptide that has the LIPO-1/LIPO-2 trial evidence behind it for visceral fat reduction. If that evidence base matters to you, tesamorelin is the only option in the category, and the cost is the trade-off for that certainty. If cost is the controlling factor, other peptides exist, but the comparison is no longer apples-to-apples.
Frequently Asked Questions
How much visceral fat does tesamorelin actually reduce?
In the pivotal LIPO-1 and LIPO-2 randomized placebo-controlled trials, tesamorelin reduced visceral adipose tissue by approximately 15–18% over 26 weeks, measured by MRI. Waist circumference typically decreased by ~2 cm in the same period.
Tesamorelin vs. semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound), which is better?
They do different things. Tesamorelin specifically reduces visceral (deep abdominal) fat while preserving muscle mass, modest scale change, significant waistline change. GLP-1s reduce total body weight more dramatically but don’t preferentially target visceral fat and can cause some lean mass loss. Some patients use them together, particularly those who reach a body-composition plateau on a GLP-1 with persistent central adiposity.
How long until I see results from tesamorelin?
Most patients don’t see meaningful visible change before week 8–12. The full effect lands around month 6 (26 weeks), which was the primary endpoint in the FDA approval trials.
Will tesamorelin help me lose weight on the scale?
Modestly. Tesamorelin is not a scale-weight drug, it’s a body-composition drug. Expect a flatter abdomen, smaller waist, and improved metabolic markers more than dramatic scale reduction.
Does the fat come back when I stop?
Yes, visceral fat tends to return over the 6–12 months after stopping tesamorelin. This is consistent with how hormonal fat-loss therapies generally work. The fat compartment that was reduced regrows when the GH signal goes back to baseline.
Is tesamorelin FDA-approved?
Yes. Tesamorelin (brand names Egrifta SV and Egrifta WR) is FDA-approved for the reduction of excess abdominal fat in patients with HIV-associated lipodystrophy. Use in HIV-negative patients for general visceral fat reduction is off-label but legally prescribable under physician judgment.
What are the side effects?
Most are mild, injection-site reactions, mild fluid retention, occasional joint stiffness or headache. The signals that matter clinically are wrist symptoms (carpal-tunnel-like), persistent edema, or elevated fasting glucose, which usually mean IGF-1 is too high and dosing needs adjustment.
How is tesamorelin dosed?
2 mg subcutaneously, once daily, at bedtime in a fasted state. Bedtime/fasted timing avoids insulin interference and stacks the pharmacological GH pulse on the body’s natural overnight GH surge.
Can tesamorelin be combined with TRT or GLP-1s?
Yes, and this is increasingly common in clinical practice. Tesamorelin works through a different mechanism than testosterone or GLP-1s and can be used alongside either under physician supervision, with appropriate monitoring.
How much does tesamorelin cost?
Brand-name tesamorelin (Egrifta SV / Egrifta WR) typically runs in the multiple-thousands-of-dollars-per-month range at retail. Insurance generally covers it only for the on-label HIV indication; off-label use is rarely covered.
Choosing the right peptide, and the right clinic
Before you decide anything about tesamorelin, get three numbers: your fasting IGF-1, your fasting glucose and HbA1c, and your waist circumference at the navel. Those three tell you whether GH-based fat-loss therapy is mechanistically appropriate for you, whether it’s metabolically safe to start, and whether visceral fat is genuinely your problem in the first place. Most people who think they need tesamorelin haven’t seen those numbers yet.
A consultation at TRTMD gets you those numbers, and the physician read on what they mean before any prescription is written.
